CS logo
small CS logo
Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital

Sevilla, Spain
Instituto de investigación en Sevilla

About Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital


  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender

Clinical Trials at Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital


During the past decade, Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 2 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Clinical Trials Sponsors and Collaborators


In terms of collaborators to trials, out of the total clinical trials conducted in "Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital" #1 collaborator was "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 2 trials as a collaborator, "Assistance Publique - Hôpitaux de Paris" with 2 trials as a collaborator, "Linkoeping University" with 2 trials as a collaborator, "University Medical Center Mainz" with 2 trials as a collaborator and "University of Angers" with 2 trials as a collaborator. Other collaborators include 35 different institutions and companies that were collaborators in the rest 39 trials.

Clinical Trials Conditions at Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital


According to Clinical.Site data, the most researched conditions in "Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital" are "Fibrosis, Liver" (2 trials), "NAFLD" (2 trials), "NASH" (2 trials), "NASH - Nonalcoholic Steatohepatitis" (2 trials) and "Steatosis of Liver" (2 trials). Many other conditions were trialed in "Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital" in a lesser frequency.

Clinical Trials Intervention Types at Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital


Most popular intervention types in "Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital" are "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "Dose Escalation Doublet: Combination of NKTR-214 + nivolumab" (1 trials), "Dose Expansion Doublet: Combination of NKTR-214 + nivolumab" (1 trials), "Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab" (1 trials), "Elafibranor" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

Clinical Trials Genders at Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital


The vast majority of trials in "Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital" are 4 trials for "All" genders.

Clinical Trials Status at Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital


Currently, there are NaN active trials in "Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital, undefined suspended trials, and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".